Total synthesis and biological evaluation of 22-hydroxyacuminatine
- PMID: 16480276
- PMCID: PMC2532531
- DOI: 10.1021/jm051116e
Total synthesis and biological evaluation of 22-hydroxyacuminatine
Abstract
A total synthesis of 22-hydroxyacuminatine, a cytotoxic alkaloid isolated from Camptotheca acuminata, is reported. The key step in the synthesis involves the reaction of 2,3-dihydro-1H-pyrrolo[3,4-b]quinoline with a brominated phthalide to generate a substituted pentacyclic 12H-5,11a-diazadibenzo[b,h]fluoren-11-one intermediate. Despite its structural resemblance to camptothecin and luotonin A, a biological evaluation of 22-hydroxyacuminatine in a topoisomerase I-deficient cell line P388/CPT45 has confirmed that the observed cytotoxicity is not due to topoisomerase I inhibition, even though 22-hydroxyacuminatine has a hydroxyl group that can theoretically hydrogen bond to Asp533. This result is consistent with the hypothesis that pi-pi stacking is more important than hydrogen-bonding interactions in determining topoisomerase I inhibitor binding in the ternary cleavage complex.
Figures
References
-
- Thomas CJ, Rahier NJ, Hecht SM. Camptothecin: Current Perspectives. Bioorg Med Chem. 2004;12:1585–1604. - PubMed
-
- Wang JC. Cellular Roles of DNA Topoisomerases: A Molecular Perspective. Nat Rev Mol Cell Biol. 2002;3:430–440. - PubMed
-
- Kollmannsberger C, Mross K, Jakob A, Kanz L, Bokemeyer C. Topotecan - A Novel Topoisomerase I Inhibitor: Pharmacology and Clinical Experience. Oncology. 1999;56:1–12. - PubMed
-
- Burke TG, Mi ZH. The Structural Basis of Camptothecin Interactions with Human Serum-Albumin - Impact on Drug Stability. J Med Chem. 1994;37:40–46. - PubMed
-
- Meng LH, Liao AY, Pommier Y. Non-Camptothecin DNA Topoisomerase I Inhibitors in Cancer Therapy. Curr Top Med Chem. 2003;3:305–320. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
